ReviewFrontiers in immunology2025
Cochlear immunology and its therapeutic revolution.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cochlear Inflammatory Microenvironment in Age-Related Hearing Loss: Mechanisms and Recent Advances.Clinical interventions in aging · 2026Review
- Vitamin D and sudden sensorineural hearing loss: emerging associations, mechanistic insights, and prospects for precision medicine - a review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past five years, cochlear immunology has experienced a paradigm shift, challenging the long-held perception of the inner ear as an "immune-privileged" site. Our review consolidates recent advancements that elucidate the cochlea's intricate local immune system, comprising resident macrophages, Tlymphocytes, and dendritic cells, in conjunction with the regulatory blood-labyrinth barrier. We investigate how immune dysregulation contributes to various auditory disorders, including autoimmune inner ear disease, inflammatory responses to cochlear implantation, noise-induced hearing loss, and age-related hearing loss. The review critically assesses therapeutic strategies, encompassing both traditional immunosuppressants and innovative immunomodulatory approaches, as well as interventions targeting fundamental aging pathways. Significant research gaps are highlighted, including the need for reliable biomarkers, a deeper understanding of immune cell heterogeneity, and the development of enhanced drug delivery systems. These advancements present promising opportunities for the development of targeted treatments for immune-mediated hearing loss, with the potential to revolutionize the clinical management of these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.